Placenta-directed gene therapy for fetal growth restriction

Area of Science:

• Obstetrics and Gynecology
• Molecular Biology
• Genetics

Background:

• Fetal growth restriction (FGR) affects approximately 8% of pregnancies globally.
• Currently, no effective treatments exist to enhance fetal growth in utero.
• Gene therapy is emerging as a potential therapeutic strategy for FGR.

Purpose of the Study:

• To review advancements in placenta-directed gene therapy for FGR.
• To explore the application of transgenes and vectors in FGR treatment.
• To outline the clinical translation pathway for gene therapy in obstetrics.

Main Methods:

• Review of preclinical studies on gene therapy for FGR.
• Analysis of adenoviral vectors encoding growth factors like VEGF and IGF.
• Assessment of safety data for maternal gene therapy.

Main Results:

• Preclinical studies demonstrate improvements in fetal growth, placental function, and neonatal outcomes with gene therapy.
• Vascular endothelial growth factor (VEGF) maternal gene therapy shows no adverse risks to mother or fetus.
• A clinical trial for VEGF maternal gene therapy is in development.

Conclusions:

• Placenta-directed gene therapy holds significant promise for treating FGR.
• Further research and clinical trials are necessary to establish safety and efficacy.
• Gene therapy could revolutionize the management of FGR in clinical obstetrics.